Neurocrine Biosciences (NBIX) News Today

Neurocrine Biosciences (NASDAQ:NBIX) saw analyst activity and clinical updates drive trading today. A string of bullish price‐target raises, solid Q2 results and an advancing Phase 3 study supported investor optimism, while a lone price‐target cut from Royal Bank of Canada provided a counterweight.

• Positive Sentiment: Morgan Stanley lifted its target from $150.00 to $158.00 and maintained an “overweight” rating, projecting strong future appreciation. Morgan Stanley Forecasts Strong Price Appreciation for NBIX
• Positive Sentiment: Stifel Nicolaus raised its target from $166.00 to $174.00 and reiterated a “buy” rating. Stifel Nicolaus Price Target Raised to $174.00
• Positive Sentiment: Piper Sandler bumped its target from $154.00 to $175.00 and kept an “overweight” stance. Piper Sandler New $175.00 Price Target
• Positive Sentiment: Guggenheim boosted its target from $165.00 to $175.00 with a “buy” rating, indicating roughly 36% upside. Benzinga Article on Guggenheim Upgrade
• Positive Sentiment: Wedbush increased its target from $137.00 to $141.00 and upheld an “outperform” rating. Wedbush Price Target Raised to $141.00
• Positive Sentiment: Cantor Fitzgerald lifted its FY2025 EPS estimate to $4.50 from $4.39, above consensus. Cantor Fitzgerald EPS Upgrade
• Positive Sentiment: Q2 revenue jumped 17%, reflecting robust sales growth. Neurocrine Q2 Revenue Jumps 17%
• Positive Sentiment: Q2 earnings‐call highlights underscored strong sales growth and strategic adjustments. Q2 2025 Earnings Call Highlights
• Positive Sentiment: The company advanced its Phase 3 schizophrenia treatment study, an important clinical milestone. Phase 3 Study Update
• Neutral Sentiment: JPMorgan raised its price target from $140.00 to $145.00 but kept a “neutral” rating. JPMorgan Price Target Increase
• Neutral Sentiment: The Analyst Verdict survey of 17 experts offered varied perspectives without altering consensus. The Analyst Verdict Article
• Negative Sentiment: Royal Bank of Canada trimmed its target from $146.00 to $144.00, though retaining an “outperform” rating. RBC Price Target Cut to $144.00